- SEK1.36bn
- SEK1.05bn
Brief: InDex Pharmaceuticals Q2 EBIT at SEK -86.9 Million
Brief: Index Pharmaceuticals Gets Cobitolimod Patent in Europe
Brief: Index Pharmaceuticals Announces License Agreement With Viatris Japan To Develop And Commercialize Cobitolimod In Japan
Brief: InDex Pharmaceuticals Q1 EBIT Loss at SEK 44.3 Million
Brief: InDex Pharmaceuticals Announces Positive Results From PK Study With Cobitolimod
Brief: Index Pharmaceuticals Q4 Oper Loss Widens To SEK 58.2 Mln
Brief: Index Pharmaceuticals Updates Timeline Of Phase III Study CONCLUDE
Brief: Index Pharmaceuticals Holding Q3 Oper Loss Narrows To SEK 4.5 Mln
Brief: Jenny Sundqvist Appointed New CEO Of InDex Pharmaceuticals
Brief: Index Pharmaceuticals Q2 Operating Loss At SEK 21.7 Mln
Brief: Index Pharmaceuticals Gets New Patent For Cobitolimod Granted In Europe
Brief: InDex Pharmaceuticals Q1 Oper Loss Widens To SEK 18.9 Mln
Brief: Index Pharmaceuticals: CFO Johan Giléus Has Been Appointed Acting CEO
Brief: Index Pharmaceuticals Prepares For Commercialisation Of Cobitolimod
Brief: Index Pharmaceuticals Q4 Oper Loss Widens To SEK 22.7 Mln
Brief: Index Pharmaceuticals Says COO Pernilla Sandwall Has Decided To Leave Company To Become CEO Of WntResearch
Brief: Index Pharmaceuticals Enrols First Patient In Late-Stage Study Of Cobitolimod
Brief: Index Pharmaceuticals Holding Q3 Operating Loss Widens To SEK 28.2 Million
Brief: Index Pharmaceuticals Gets Patent For Cobitolimod In Canada